BRIDGEBIO PHARMA - BBP-418 MET ALL PRIMARY AND SECONDARY ENDPOINTS AT 12-MONTH INTERIM PHASE 3 FORTIFY TRIAL

Reuters · 2d ago

Please log in to view news